Hindustan Unilever's board approved on 12 February the acquisition of the remaining 49% of Zywie Ventures, the company behind plant-based nutrition brand OZiva, for ₹824 crore, making it a wholly owned subsidiary.
Why Hindustan Unilever Ltd is buying Zywie Ventures (OZiva)
HUL entered health and wellbeing in 2023 and describes it as a fast-growing but still nascent consumer category. The company said full ownership of OZiva fits its strategy of making fewer, bigger bets and would let it apply its science, distribution and market-development capabilities to the brand.
“Health & Wellbeing is an important growth vector for us, driven by rising consumer interest in everyday wellness.”
Deal terms and financing
The price was set under a valuation framework agreed when HUL bought 51% of the company in December 2022 for ₹264.28 crore. The second tranche values OZiva at about ₹1,682 crore. Sellers included founders Aarti Gill and Mihir Gadani and investors Eight Roads Ventures India, F-Prime Capital Partners and Life Sciences Fund VI. In the same announcement HUL agreed to sell its 19.8% minority stake in Nutritionalab to USV for ₹307 crore.
Regulatory approvals and timing
HUL initially said the deals would close by March 2026, subject to customary conditions; Inc42 reported on 13 February that the company had informed the exchanges the OZiva purchase was complete.
Market context
OZiva's revenue grew at about 130% a year over the past two years to roughly ₹480 crore in 2025. HUL first entered the category with the 51% OZiva purchase announced in December 2022.
